MedTrace Logo

Sequential Therapies After Osteoanabolic Treatment

NCT06164795 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2026-07-22

No results posted yet for this study

Summary

12-month prospective, open-label, multicenter, international, observational study evaluating sequential treatments after osteoanabolics

Conditions

  • Osteoporosis, Postmenopausal

Interventions

DRUG

Zoledronate

intravenous infusion

DRUG

Denosumab

subcutaneous injection

DRUG

Teriparatide

subcutaneous injection

DRUG

Romosozumab

subcutaneous injection

DRUG

Abaloparatide Injection (80 mcg)

daily subcutaneous injection

Sponsors & Collaborators

  • Laikο General Hospital, Athens

    collaborator OTHER

  • 251 Hellenic Air Force & VA General Hospital

    collaborator OTHER

  • KAT General Hospital

    collaborator OTHER

  • Campus Bio-Medico University

    collaborator OTHER

  • Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico Milano

    collaborator UNKNOWN

  • Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine, Italy

    collaborator OTHER

  • University of Siena

    collaborator OTHER

  • 424 General Military Hospital

    lead OTHER

Principal Investigators

  • Willem Lems, Prof · ECTS Clinical Action Group

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-25
Primary Completion
2027-06-01
Completion
2027-12-31

Countries

  • Greece
  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06164795 on ClinicalTrials.gov